Please assess the completion status of the following clinical trial:

Trial Title: Effects of Victoza® Versus Lyxumia® on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial.~* Male or female aged 18-65 years (both inclusive)~* T2DM diagnosis~Exclusion Criteria:~* Contraindications (including known or suspected hypersensitivity) to GLP-1 mimetics~* Use of GLP-1 mimetics or DPP-IV inhibitors~* Clinically relevant dysglycaemia as indicated by HbA1C ≥ 10%

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Liraglutide (Type: EXPERIMENTAL): The highest injected once daily dose will be 1.8 mg s.c. for liraglutide.
- Lixisenatide (Type: EXPERIMENTAL): The highest injected once daily dose will be 20µg s.c. for lixisenatide.

Based on this trial design, predict the completion outcome and termination type (if applicable).